Acute and chronic results of adjuvant radiotherapy after mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap reconstruction for breast cancer

Michele Y. Halyard, Kathy E. McCombs, William W. Wong, Edward W. Buchel, Barbara A Pockaj, Sujay A. Vora, Richard J. Gray, Steven E. Schild

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A retrospective review of the treatment of 15 breast cancer patients who received postoperative radiotherapy after a mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap breast reconstruction was undertaken to determine the effects of postoperative irradiation on flap viability and cosmesis. Fourteen patients had pedicle TRAM flaps, and one patient had a free TRAM flap. Surgical complications, acute and chronic side effects of radiotherapy, and cosmetic outcome were evaluated. The median interval between the TRAM flap procedure and radiotherapy was 7 months. The median total radiation dose was 60 Gy. All patients underwent three-dimensional radiotherapy treatment planning to determine the optimal dose distribution. Mild erythema developed in 9 patients (60%), moderate erythema developed in 2 (13%), and severe erythema developed in 1 (7%). Dry desquamation developed in 6 patients (40%), whereas moist desquamation developed in none. At median follow-up of 26.4 months, only 2 (13%) of the 15 patients had fat necrosis within the TRAM flap that was not present before radiotherapy. Fourteen patients (93%) retained their flap, and 13 patients (87%) rated their cosmetic outcome as "good" to "excellent." We conclude that TRAM flaps can be irradiated with few complications and acceptable cosmetic results.

Original languageEnglish (US)
Pages (from-to)389-394
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume27
Issue number4
DOIs
StatePublished - Aug 2004

Fingerprint

Rectus Abdominis
Adjuvant Radiotherapy
Myocutaneous Flap
Mastectomy
Breast Neoplasms
Radiotherapy
Erythema
Cosmetics
Fat Necrosis
Mammaplasty
Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Acute and chronic results of adjuvant radiotherapy after mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap reconstruction for breast cancer. / Halyard, Michele Y.; McCombs, Kathy E.; Wong, William W.; Buchel, Edward W.; Pockaj, Barbara A; Vora, Sujay A.; Gray, Richard J.; Schild, Steven E.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 27, No. 4, 08.2004, p. 389-394.

Research output: Contribution to journalArticle

Halyard, Michele Y. ; McCombs, Kathy E. ; Wong, William W. ; Buchel, Edward W. ; Pockaj, Barbara A ; Vora, Sujay A. ; Gray, Richard J. ; Schild, Steven E. / Acute and chronic results of adjuvant radiotherapy after mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap reconstruction for breast cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2004 ; Vol. 27, No. 4. pp. 389-394.
@article{089105566cf84310b0274076e79b8c93,
title = "Acute and chronic results of adjuvant radiotherapy after mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap reconstruction for breast cancer",
abstract = "A retrospective review of the treatment of 15 breast cancer patients who received postoperative radiotherapy after a mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap breast reconstruction was undertaken to determine the effects of postoperative irradiation on flap viability and cosmesis. Fourteen patients had pedicle TRAM flaps, and one patient had a free TRAM flap. Surgical complications, acute and chronic side effects of radiotherapy, and cosmetic outcome were evaluated. The median interval between the TRAM flap procedure and radiotherapy was 7 months. The median total radiation dose was 60 Gy. All patients underwent three-dimensional radiotherapy treatment planning to determine the optimal dose distribution. Mild erythema developed in 9 patients (60{\%}), moderate erythema developed in 2 (13{\%}), and severe erythema developed in 1 (7{\%}). Dry desquamation developed in 6 patients (40{\%}), whereas moist desquamation developed in none. At median follow-up of 26.4 months, only 2 (13{\%}) of the 15 patients had fat necrosis within the TRAM flap that was not present before radiotherapy. Fourteen patients (93{\%}) retained their flap, and 13 patients (87{\%}) rated their cosmetic outcome as {"}good{"} to {"}excellent.{"} We conclude that TRAM flaps can be irradiated with few complications and acceptable cosmetic results.",
author = "Halyard, {Michele Y.} and McCombs, {Kathy E.} and Wong, {William W.} and Buchel, {Edward W.} and Pockaj, {Barbara A} and Vora, {Sujay A.} and Gray, {Richard J.} and Schild, {Steven E.}",
year = "2004",
month = "8",
doi = "10.1097/01.COC.0000071946.11078.7E",
language = "English (US)",
volume = "27",
pages = "389--394",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Acute and chronic results of adjuvant radiotherapy after mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap reconstruction for breast cancer

AU - Halyard, Michele Y.

AU - McCombs, Kathy E.

AU - Wong, William W.

AU - Buchel, Edward W.

AU - Pockaj, Barbara A

AU - Vora, Sujay A.

AU - Gray, Richard J.

AU - Schild, Steven E.

PY - 2004/8

Y1 - 2004/8

N2 - A retrospective review of the treatment of 15 breast cancer patients who received postoperative radiotherapy after a mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap breast reconstruction was undertaken to determine the effects of postoperative irradiation on flap viability and cosmesis. Fourteen patients had pedicle TRAM flaps, and one patient had a free TRAM flap. Surgical complications, acute and chronic side effects of radiotherapy, and cosmetic outcome were evaluated. The median interval between the TRAM flap procedure and radiotherapy was 7 months. The median total radiation dose was 60 Gy. All patients underwent three-dimensional radiotherapy treatment planning to determine the optimal dose distribution. Mild erythema developed in 9 patients (60%), moderate erythema developed in 2 (13%), and severe erythema developed in 1 (7%). Dry desquamation developed in 6 patients (40%), whereas moist desquamation developed in none. At median follow-up of 26.4 months, only 2 (13%) of the 15 patients had fat necrosis within the TRAM flap that was not present before radiotherapy. Fourteen patients (93%) retained their flap, and 13 patients (87%) rated their cosmetic outcome as "good" to "excellent." We conclude that TRAM flaps can be irradiated with few complications and acceptable cosmetic results.

AB - A retrospective review of the treatment of 15 breast cancer patients who received postoperative radiotherapy after a mastectomy and transverse rectus abdominis myocutaneous (TRAM) flap breast reconstruction was undertaken to determine the effects of postoperative irradiation on flap viability and cosmesis. Fourteen patients had pedicle TRAM flaps, and one patient had a free TRAM flap. Surgical complications, acute and chronic side effects of radiotherapy, and cosmetic outcome were evaluated. The median interval between the TRAM flap procedure and radiotherapy was 7 months. The median total radiation dose was 60 Gy. All patients underwent three-dimensional radiotherapy treatment planning to determine the optimal dose distribution. Mild erythema developed in 9 patients (60%), moderate erythema developed in 2 (13%), and severe erythema developed in 1 (7%). Dry desquamation developed in 6 patients (40%), whereas moist desquamation developed in none. At median follow-up of 26.4 months, only 2 (13%) of the 15 patients had fat necrosis within the TRAM flap that was not present before radiotherapy. Fourteen patients (93%) retained their flap, and 13 patients (87%) rated their cosmetic outcome as "good" to "excellent." We conclude that TRAM flaps can be irradiated with few complications and acceptable cosmetic results.

UR - http://www.scopus.com/inward/record.url?scp=3843103994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3843103994&partnerID=8YFLogxK

U2 - 10.1097/01.COC.0000071946.11078.7E

DO - 10.1097/01.COC.0000071946.11078.7E

M3 - Article

VL - 27

SP - 389

EP - 394

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 4

ER -